Whenever one of my biotech companies have good news. It almost always makes me smile. Yesterday it was GW. The shares of GW Pharmaceuticals (GWPH) are soaring on news that its cannabis-derived drug significantly diminished the seizure amount in children with a rare form of epilepsy in a phase-three trial. Epidiolex…
Maybe I’m a little late. But in december Nektar announced the following: Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors. NKTR-214 is a novel CD122-biased cytokine designed to preferentially activate…
View: Annual Data | Quarterly Data All numbers in thousands Period Ending Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Total Revenue 84 39 39 39 Cost of Revenue 16 16 16 16 Gross Profit 69 24 24 24 Operating Expenses Research Development 4,336 3,544 3,378…
Last october my neighbour (E) came up with the idea of buying Nyrstar. I started with a small portion via a CFD. In this case a Dutch leveraged product called a “Turbo” (a Turbo is a product whereby investors benefit from the increase or decline in value of an underlying asset…
It has been quite a while since I wrote a new post mainly because it is the season for my real job (temporary structure specialist) which took most of my time but there is one more reason I would like to share with you. I have found a new girlfriend….
As I have said in my earlier posts. I really like this company for its pipeline. Within the next 2 years I expect them to have started multiple Phase 3 studies. This is just the beginning. Let’s hope their PR machine works (I’ll help them a bit) 🙂 Check out…
